Related Experiment Video
Updated: Jul 15, 2026
08:50
Prostaglandin Extraction and Analysis in Caenorhabditis elegans
Published on: June 25, 2013
Polymorphisms predicted to alter function in prostaglandin E2 synthase and prostaglandin E2 receptors
Jeannette Bigler1, Justin G Sibert, Elizabeth M Poole
1Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. jbigler@amgen.com
Pharmacogenetics and Genomics
|April 27, 2007
Summary
Researchers identified genetic variants in prostaglandin E2 (PGE2) synthesis and signaling pathways. Some variants may impact protein function, potentially influencing inflammation, cancer, and drug response.
Area of Science:
- Pharmacology
- Pharmacogenetics
- Epidemiology
- Molecular Biology
- Genetics
Background:
- Prostaglandin synthesis is a key target for nonsteroidal anti-inflammatory drugs.
- Prostaglandin E2 (PGE2) is implicated in carcinogenesis.
- Genetic variations in PGE2 pathways are of significant interest.
Purpose of the Study:
- To identify genetic variants in genes involved in prostaglandin E2 synthesis and signaling.
- To investigate the potential functional impact of these variants.
Main Methods:
- Resequencing of coding regions for human prostaglandin E2 synthase (PGES) and EP1, EP2, and EP4 receptors.
- Analysis of genetic variants in African-American and Caucasian populations.
- In silico prediction of variant impact using SIFT and PolyPhen programs.
Main Results:
- Identified 23 genetic variants, including 6 non-synonymous polymorphisms.
- Specific non-synonymous variants in PGES, EP1, and EP2 were found predominantly in African-Americans.
- Both populations carried non-synonymous polymorphisms in EP4.
- SIFT and PolyPhen predicted functional impact for several amino acid changes (e.g., p.Phe119Val in EP1, p.Ala44Glu in EP2).
Conclusions:
- Several identified genetic variants, particularly non-synonymous polymorphisms in PGES, EP1, EP2, and EP4, may alter protein function.
- These variants could be relevant to inflammatory conditions and carcinogenesis.
- The findings have implications for pharmacogenetics and understanding individual drug responses.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...